NCT04774952 2025-04-15Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid TumorsRevolution Medicines, Inc.Phase 1 Completed58 enrolled
NCT03634982 2022-09-01Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid TumorsRevolution Medicines, Inc.Phase 1 Unknown133 enrolled
NCT00035334 2006-02-14Study of the Safety and Efficacy of NC-503 in Secondary (AA) AmyloidosisBellus Health Inc. - a GSK companyPhase 2/3 Completed150 enrolled